TICADAX 90 Tablets provide an established, clinically unified antiplatelet therapy carefully developed for the continuous management, secondary prevention, and long-term stabilization of patients with atherothrombotic conditions or Acute Coronary Syndrome (ACS). When an arterial plaque ruptures or a cardiac stent is deployed, the body’s localized coagulation cascade triggers an intense gathering of platelets. This rapid collection can form a sudden structural blood clot, blocking vital coronary blood flow and triggering an acute heart attack or stroke. This advanced formulation delivers a reversible, direct-acting platelet inhibitor within a standard 90 mg unit to maintain optimal vascular flow profiles safely over a steady care routine.
The active component, Ticagrelor (90 mg), functions dynamically via highly targeted cellular tracks:
-
Reversible P2Y12 Receptor Antagonism: Unlike traditional thienopyridine antiplatelet drugs (like clopidogrel) which bind irreversibly for the life of the platelet, Ticagrelor is a cyclo-pentyl-triazolo-pyrimidine (CPTP) that binds reversibly to the $P2Y_{12}$ adenosine diphosphate (ADP) receptor on platelet membranes. This blockade targets separate allosteric modulation tracks, preventing ADP-mediated signaling lines.
-
Inhibition of Platelet Activation: By preventing ADP from activating the $GP IIb/IIIa$ receptor complex, it systematically locks the platelet in an inactive state. This physical containment blocks fibrinogen cross-linking webs, arresting platelet aggregation and clot growth to shield ischemic heart muscle zones completely from upcoming vascular blockage around the clock.
Key Benefits
-
Premium Clot Prevention Core: Offers a rapid onset and more consistent antiplatelet tracking effect compared to older generation alternative therapies.
-
Reversible Binding Architecture: The reversible mechanism track provides greater clinical flexibility and more predictable recovery of platelet function over titration zones.
-
Advanced Post-Stent Shield: Minimizes the highly dangerous long-term risk of sudden stent thrombosis in patients who have undergone percutaneous coronary intervention.
-
Robust Ischemic Protection: Significantly reduces total cardiovascular risk metrics, actively safeguarding target pathways in the brain and heart muscle.
-
Precise 14-Tablet Layout: Packaged in a specialized 14-tablet blister configuration to provide exact, easy monitoring of twice-daily care cycles.
Directions for Use
-
Take exactly as directed by your cardiologist or primary healthcare specialist.
-
TICADAX 90 is typically prescribed as a twice-daily regimen (one tablet in the morning and one at night).
-
Can be taken comfortably either with or without food. Try to administer your doses at the exact same times every day to build a perfectly flat active plasma baseline.
-
Swallow the tablet whole with a full glass of plain water. Do not crush or chew it.
-
Important Synergy Note: This medication is almost always prescribed alongside a low-dose daily aspirin configuration (dual antiplatelet therapy / DAPT). Maintain complete regular consistency with both elements.
Safety & Precautions
-
Do not stop taking this medication suddenly without explicit confirmation from your cardiologist. Premature discontinuation of antiplatelet therapies introduces an extremely high risk of a sudden heart attack or fatal stent clotting.
-
Bleeding Risk Warning: As an advanced blood thinner, TICADAX 90 makes it easier for you to bruise or bleed. You may experience routine nosebleeds or take longer to stop bleeding from minor cuts. Avoid contact sports or activities that carry heavy risk profiles for physical injury.
-
Inform all medical professionals (including dentists or surgeons) that you are taking Ticagrelor well in advance of scheduling any invasive procedures; it may need to be paused temporary depending on tracking timelines.
-
Dyspnea Parameter: Some patients may notice a temporary, mild sensation of shortness of breath (dyspnea) during the first few weeks of therapy. This is usually self-limiting and should be evaluated by your specialist if it becomes persistent.
-
Contraindicated in patients with a history of active pathological bleeding (such as peptic ulcers or intracranial hemorrhage) or severe hepatic impairment.
-
Keep out of reach of children.
Storage
-
Store in a cool, dry place below 30°C.
-
Protect from direct sunlight, excessive heat sources, and ambient environmental room moisture pools.
-
Always keep the tablets safely sealed inside their original protective blister packing layout until the exact moment of intake to shield the core from air oxidation.
